Mersana Therapeutics to Host Virtual Analyst and Investor Event
Debra L. Richardson, MD, Associate Professor and Section Chief, Division of Gynecologic Oncologyat the OU Health Stephenson Cancer Centerand the Sarah Cannon Research Institute, will review updated data from the ovarian cancer cohort of the Phase 1 expansion study evaluating XMT-1536, the Company’s first-in-class ADC candidate targeting NaPi2b.
- Mersana’s management team will detail the Company’s plans for the registration-enabling study of XMT-1536 in platinum-resistant ovarian cancer and outline its objectives for longer-term life cycle management studies to evaluate the potential of XMT-1536 in platinum-sensitive ovarian cancer.
- Mersana’s management team will disclose preclinical data supporting the development of the Company’s first-in-class B7-H4 DolaLock ADC development candidate.
- Mersana’s management team will outline the Company’s anticipated 2021 goals and milestones for its clinical and early-stage ADC programs.
Webcast and Conference Call Details
A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at https://ir.mersana.com/events-and-presentations. Analyst and Investors may ask a question during the live Q&A by dialing (855) 940-5308 (toll-free domestic) or (929) 517-9745 (international) and providing the Conference ID 6265117.
About Mersana Therapeutics
Investor & Media Contact
Source: Mersana Therapeutics, Inc.